Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. develops investigational biologics intended to enhance regulatory T-cell, or Treg, function in neurodegenerative disorders. Company news centers on COYA 302, including clinical and regulatory updates in amyotrophic lateral sclerosis and frontotemporal dementia, biomarker publications, and research on systemic inflammation, lipid peroxidation, axonal injury, and Treg dysfunction.
Coya updates also cover its Treg-focused therapeutic platforms, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Recurring business developments include collaboration activity with Dr. Reddy’s Laboratories, milestone-related revenue disclosures, operating results, stockholder communications, and board or governance changes.
Coya Therapeutics (NASDAQ:COYA) has received FDA acceptance of its Investigational New Drug (IND) application for COYA 302, a proprietary immunomodulatory biologic combination therapy for treating Amyotrophic Lateral Sclerosis (ALS). The acceptance enables the company to proceed with a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the treatment's efficacy and safety.
The milestone triggers a $4.2 million payment to Coya from its partner Dr. Reddy's Laboratories (DRL). The development represents a significant step in Coya's partnership with DRL to advance potential treatments for ALS patients.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on regulatory T cell enhancement for neurodegenerative disorders, reported Q2 2025 financial results and corporate updates. The company ended Q2 with $29.8 million in cash and posted a net loss of $6.1 million, wider than the $2.9 million loss in Q2 2024.
Key developments include the FDA submission for COYA 302 Phase 2 trial in ALS patients, with a decision expected by August 29, 2025. Upon IND acceptance and first patient dosing, Coya will receive $8.4 million in milestone payments from Dr. Reddy's Laboratories. The company also secured a U.S. patent for a stable ready-to-use liquid IL-2 formulation and plans to submit an IND for Frontotemporal Dementia by year-end.
Coya Therapeutics (NASDAQ: COYA) has announced the publication of a significant research study examining the relationship between inflammation, oxidative stress, and Parkinson's Disease (PD) progression. The study, partially funded by Coya and published in Frontiers of Immunology, reveals important findings about immune dysfunction in PD pathogenesis.
The research demonstrates that peripheral blood monocytes from PD patients show distinct inflammatory patterns compared to healthy controls, with key findings including: upregulation of pro-inflammatory cytokines (IL-6 and IL-1b), increased expression of chemokine receptor CCR2, and varying levels of oxidative stress markers throughout disease progression.
The company is developing COYA 302, a dual immunomodulatory treatment designed to enhance regulatory T cell (Treg) function and suppress inflammation produced by activated monocytes and macrophages. This approach aligns with the study's findings regarding the role of peripheral inflammation in PD pathophysiology.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on developing biologics for regulatory T cell function enhancement, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025.
Interested parties can schedule one-on-one meetings with Coya's management team through their BTIG representatives.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on developing biologics for regulatory T cell function enhancement, announces its participation in the H.C. Wainwright 3rd Annual BioConnect Conference on May 20, 2025. CEO Arun Swaminathan will engage in a fireside chat at 12:30pm ET at the Nasdaq World Headquarters in New York City.
The presentation will be available via webcast, with management offering one-on-one meeting opportunities. The webcast will be accessible through Coya's website and remain available for 90 days after the event.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on developing biologics for regulatory T cell function enhancement, has announced its participation in two upcoming conferences in May 2025. The company's leadership, including CEO Dr. Arun Swaminathan and CFO David Snyder, will be available for one-on-one meetings with registered investors at:
1. The D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York
2. The Mizuho Neuro & Opthalmology Summit from May 20-21, 2025, at the Park Lane Hotel in New York
Coya Therapeutics (NASDAQ: COYA) has announced positive interim results from an investigator-initiated open-label study testing low-dose IL-2 and CTLA4-Ig combination treatment in Frontotemporal Dementia (FTD) patients. The study, conducted at Houston Methodist Neurological Institute, showed promising results in the first cohort of 5 patients.
Key findings include:
- Statistically significant increase in Treg numbers and suppressive function
- Minimal to no cognitive decline throughout the study period
- Well-tolerated treatment with no serious adverse events
- All 5 patients completed the 22-week treatment course
This is particularly notable as FTD patients typically experience rapid cognitive decline, with historical data showing an average 3.57-point worsening over 12 months on the CDR-FTLD scale. The treatment's success in maintaining cognitive function suggests potential therapeutic value for FTD, which currently has no approved treatments.